Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors

JCO Precis Oncol. 2023 Sep:7:e2300217. doi: 10.1200/PO.23.00217.

Authors

Marcia S Brose¹, David S Hong¹, Alexander Drilon¹

Affiliation

¹ Marcia S. Brose, MD, PhD, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA; David S. Hong, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Weill Cornell Medical College, New York, NY.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Neoplasms* / drug therapy
Neoplasms* / genetics
Receptor Protein-Tyrosine Kinases
Tropomyosin*

Substances

Tropomyosin
tyrosine receptor
Receptor Protein-Tyrosine Kinases

Grants and funding